GlassScriptPhysician profile
Kevin Park
NPI 1548840705
$1,895.78
in general payments reported to CMS, 2019-2025
17 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.79 · 2023: $57.98 · 2024: $427 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $714.58 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $294.66 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $158.97 | 2023-2025 | Freestyle Libre 3 |
| Zimmer Biomet Holdings, INC. | $139.88 | 2025 | Persona |
| Lilly USA, LLC | $111.00 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $94.14 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $83.95 | 2023-2025 | Veozah |
| Henry Schein, INC. | $46.16 | 2025 | |
| Merck Sharp & Dohme LLC | $43.08 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.31 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $34.05 | 2022-2023 | Camzyos |
| Amgen INC. | $33.51 | 2025 | Repatha |
| Pfizer INC. | $27.94 | 2025 | |
| Daiichi Sankyo INC. | $22.87 | 2022 | |
| Dexcom, INC. | $22.43 | 2025 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $15.94 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.31 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.